Close Menu

stock offering

The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.

Biocept closed a $14.8 million public offering earlier this year and recently reported ending the second quarter with $2.6 million in cash and cash equivalents.

The firm will sell more than 14 million shares of its common stock for $4.25 per share.

The firm did not disclose how many shares it planned to sell or how much money it expects to raise.

The filing follows the firm's recent close of a $2 million non-convertible debt instrument and CE marking for its tuberculosis test.

Proceeds from the offering, expected to close on or about Aug. 14, could be used to fund acquisitions, to repay existing debts, or for working capital.

The company had previously said that it expected gross proceeds of up to $22.6 million if rights to all 25,000 securities units were exercised.

Proceeds from the offering could be used to fund acquisitions, to repay existing debts, or for working capital.

The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.

The firm has reached a deal with certain investors for the purchase of units comprising OncoCyte common shares and warrants to purchase shares.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.